Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada; Systematic Overviews through Advancing Research Technology, Child Health Evaluative Sciences, The Research Institute, The Hospital For Sick Children, Toronto, Canada.
Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada.
J Hosp Infect. 2016 Feb;92(2):130-9. doi: 10.1016/j.jhin.2015.08.028. Epub 2015 Oct 23.
Postoperative infections, particularly surgical site infections (SSIs), cause significant morbidity and mortality. Probiotics or synbiotics are a potential prevention strategy.
To evaluate the efficacy of probiotics/synbiotics for reducing postoperative infection risk following abdominal surgery.
We searched AMED, Central, CINAHL, Embase, Medline, and grey literature for randomized controlled trials of elective abdominal surgery patients administered probiotics or synbiotics compared to placebo or standard care. Primary outcome was SSIs. Secondary outcomes were adverse events, respiratory tract infections (RTIs), urinary tract infections (UTIs), combined infections, length of hospital stay, and mortality. Using random-effects meta-analyses, we estimated the relative risk (RR) or mean difference (MD) and 95% confidence interval (CI). Tests were performed for heterogeneity, subgroup and sensitivity analyses were conducted, and the overall evidence quality was graded.
We identified 20 trials (N = 1374 participants) reporting postoperative infections. Probiotics/synbiotics reduced SSIs (RR: 0.63; 95% CI: 0.41-0.98; N = 15 studies), UTIs (RR: 0.29; 95% CI: 0.15-0.57; N = 11), and combined infections (RR: 0.49; 95% CI: 0.35-0.70; N = 18). There was no difference between groups for adverse events (RR: 0.89; 95% CI: 0.61-1.30; N = 6), RTIs (RR: 0.60; 95% CI: 0.36-1.00; N = 14), length of stay (MD: -1.19; 95% CI: -2.94 to 0.56; N = 12), or mortality (RR: 1.20; 95% CI: 0.58-2.48; N = 15).
Our review suggests that probiotics/synbiotics reduce SSIs and UTIs from abdominal surgeries compared to placebo or standard of care, without evidence of safety risk. Overall study quality was low, owing mostly to imprecision (few patients and events, or wide CIs); thus larger multi-centered trials are needed to further assess the certainty in this estimate.
术后感染,特别是手术部位感染(SSI),会导致严重的发病率和死亡率。益生菌或合生剂是一种潜在的预防策略。
评估益生菌/合生剂在减少腹部手术后感染风险方面的疗效。
我们检索了 AMED、CENTRAL、CINAHL、Embase、Medline 和灰色文献,以评估择期腹部手术患者使用益生菌或合生剂与安慰剂或标准护理相比的效果。主要结局是 SSI。次要结局为不良事件、呼吸道感染(RTI)、尿路感染(UTI)、合并感染、住院时间和死亡率。采用随机效应荟萃分析,我们估计了相对风险(RR)或平均差异(MD)和 95%置信区间(CI)。进行了异质性检验、亚组分析和敏感性分析,并对整体证据质量进行了分级。
我们确定了 20 项试验(N=1374 名参与者),报告了术后感染。益生菌/合生剂可降低 SSI(RR:0.63;95%CI:0.41-0.98;N=15 项研究)、UTI(RR:0.29;95%CI:0.15-0.57;N=11 项研究)和合并感染(RR:0.49;95%CI:0.35-0.70;N=18 项研究)。不良事件(RR:0.89;95%CI:0.61-1.30;N=6)、RTI(RR:0.60;95%CI:0.36-1.00;N=14)、住院时间(MD:-1.19;95%CI:-2.94 至 0.56;N=12)或死亡率(RR:1.20;95%CI:0.58-2.48;N=15)在两组间无差异。
我们的综述表明,与安慰剂或标准护理相比,益生菌/合生剂可降低腹部手术的 SSI 和 UTI,但没有安全性风险的证据。总体研究质量较低,主要是由于不精确(患者和事件较少,或 CI 较宽);因此,需要更大规模的多中心试验来进一步评估这一估计的确定性。